These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 24602388)
21. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. Kalra S J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761 [TBL] [Abstract][Full Text] [Related]
22. The physiologic role of incretin hormones: clinical applications. Cefalu WT J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839 [TBL] [Abstract][Full Text] [Related]
26. Incretin-based therapies: where will we be 50 years from now? Meier JJ; Nauck MA Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073 [TBL] [Abstract][Full Text] [Related]
27. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249 [TBL] [Abstract][Full Text] [Related]
28. Incretin-based therapy of type 2 diabetes mellitus. Knop FK; Vilsbøll T; Holst JJ Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672 [TBL] [Abstract][Full Text] [Related]
30. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Pratley RE J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254 [No Abstract] [Full Text] [Related]
31. Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. Mulvihill EE Peptides; 2018 Feb; 100():158-164. PubMed ID: 29412815 [TBL] [Abstract][Full Text] [Related]
32. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Davidson JA; Parente EB; Gross JL Arq Bras Endocrinol Metabol; 2008 Aug; 52(6):1039-49. PubMed ID: 18820816 [TBL] [Abstract][Full Text] [Related]
33. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes]. Scheen AJ; Paquot N Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969 [TBL] [Abstract][Full Text] [Related]
34. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR? Mora PF; Johnson EL Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769 [TBL] [Abstract][Full Text] [Related]
35. Do we know the true mechanism of action of the DPP-4 inhibitors? Andersen ES; Deacon CF; Holst JJ Diabetes Obes Metab; 2018 Jan; 20(1):34-41. PubMed ID: 28544214 [TBL] [Abstract][Full Text] [Related]
36. Incretin based therapies: bone protective effects. Chakhtoura M; Azar ST Endocr Metab Immune Disord Drug Targets; 2013 Dec; 13(4):289-94. PubMed ID: 24138054 [TBL] [Abstract][Full Text] [Related]
37. The incretin effect in critically ill patients: a case-control study. Nielsen ST; Janum S; Krogh-Madsen R; Solomon TP; Møller K Crit Care; 2015 Nov; 19():402. PubMed ID: 26567860 [TBL] [Abstract][Full Text] [Related]
38. Targeting postprandial glycaemia in children with diabetes: Opportunities and challenges. Geyer MC; Rayner CK; Horowitz M; Couper JJ Diabetes Obes Metab; 2018 Apr; 20(4):766-774. PubMed ID: 29072820 [TBL] [Abstract][Full Text] [Related]
39. Combination pharmacotherapy with incretins: what works best and when? Over RK; Ratner RE Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584 [TBL] [Abstract][Full Text] [Related]
40. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Koska J; Sands M; Burciu C; Reaven P Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]